Glenmark gains at Fulford’s cost - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark gains at Fulford’s cost

May 16, 2000

The dermatology segment (which deals with skin infections) of the pharmaceutical formulation industry has been witnessing a heavy dose of competition. While the overall formulation segment has grown at 9.8% for FY2000, this segment has grown at only 8.2%. While the market leader Glaxo seems to have slightly increased its market share, a relatively smaller company, Glenmark Pharmaceuticals seems to be a major gainer at the cost of its bigger rivals Fulford and Ranbaxy. This seems to be primarily due to the marketing push the company has been given to its products particularly Candid, its dermatological brand which seems to be following in Glaxo’s footsteps.

As per the ORG data (see table) Glaxo remains the market leader by far, with a 16.9% market share in the dermatology segment. This is due to the fact that its Betnovate range of formulations have achieved near OTC status (Over the Counter) despite being prescription brands.

  Value (Rs m) Market Share Growth
Overall Value 7,549 100.0% 8.2%
Glaxo–Wellcome 1,278 16.9% 8.9%
Fulford 649 8.6% -7.3%
Ranbaxy–Croslands 471 6.2% 3.0%
Glenmark Pharma 434 5.8% 26.2%

Source ORG RSA Mar 2000

The surprise has however been an over 25% growth for Candid. Though one can argue that Glenmark’s growth has been from a much lower base (since Glaxo’s dermatological revenues almost equal the entire revenues of the Glenmark) this just shows the importance of brand building and establishing mind recall for pharma products and the benefits it yields during a slowdown in the industry.


Equitymaster requests your view! Post a comment on "Glenmark gains at Fulford’s cost". Click here!

  

More Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

I Believe These Stocks Will Deliver the Most Outsized Returns in 2021 and Beyond (Profit Hunter)

Sep 23, 2020

Rules of the racetrack can help you bag the biggest gainers of the coming decade.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 1, 2020 10:37 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - ADCOCK INGRAM COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS